Clearside Biomedical Unveils Exciting Plans for Odyssey Phase 2b Clinical Trial of CLS-AX Axitinib Injectable Suspension in Wet AMD
Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) Clearside Biomedical, Inc. is set to begin enrolling participants for the ODYSSEY Phase 2b clinical trial this quarter. The trial will focus on the evaluation of CLS-AX, an axitinib injectable suspension, for the treatment of various eye conditions. Topline results…